Inactive Instrument

Highlights Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sector Update: Health Care Stocks Mixed Wednesday Afternoon	Apr. 17	MT
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	Apr. 17	MT
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	Apr. 17	CI
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	Feb. 26	MT
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	Feb. 26	MT
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q4 Revenue $4.1M	Feb. 26	MT
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	Nov. 06	MT
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	Nov. 06	CI
Celldex Therapeutics Q3 Net Loss Widens, Revenue Rises	Nov. 02	MT
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q3 Revenue $1.5M	Nov. 02	MT
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023	23-09-26	CI
Wall Street tries to stay in the green	23-08-22
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q2 Revenue $0.3M	23-08-08	MT
Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria	23-07-11	CI
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis	23-07-06	CI
Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023	23-06-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Highlights

Filters